Fig. 5

Celecoxib suppresses autophagy in KBM5 and KBM5-T315I cells. a KBM5 and KBM5-T315I cells were treated with 0, 20, 40, 60 μM celecoxib for 24 h. b The two cell lines were treated with 40 μM celecoxib for 6, 12, 24, 48 h. c Two samples for human CML patients were incubated with 80 μM celecoxib for 24 h. d KBM5 and KBM5-T315I cells were added with 20 μM CQ and/or 40 μM celecoxib for 24 h. a–d Cell lysates were subjected to Western blot analysis with indicated antibodies. The results shown are representative of three independent experiments